 Patients must have tumors that can be biopsied with a minimal to small amount of risk and must have a malignancy that expresses HIF-1 alpha protein as measured by immunohistochemistry determined on archival tissue, at least greater than 10 of cells show positive staining for HIF-1 alpha. 